ALZFORUM

Window to the Brain Shows Dystrophic Neurites Shrinking

Combining their individual fortés, the laboratories of Dave Holtzman at Washington University, St. Louis, and Brian Bacskai and Brad Hyman at Massachusetts General Hospital, Charlestown, treat us to ...
Medindia

Medications and their Potential to Cause Increase 'Dystrophic calcification'

This page lists all known medications that could potentially lead to 'Dystrophic calcification' as a side effect. It's important to note that mild side effects are quite common with medications. The ...
Nature

A dystrophic muscle broadens the contribution and activation of immune cells reacting to rAAV gene transfer

Recombinant adeno-associated viral vectors (rAAVs) are used for therapeutic gene transfer in skeletal muscle, but it is unclear if immune reactivity to gene transfer and persistence of transgene are ...
ALZFORUM

Focal Adhesion Proteins: Is this How Amyloid Causes Dystrophic Neurites?

Focal adhesion (FA) proteins may be critical elements in the production of dystrophic neurites in Alzheimer's disease, according to research presented in the January 15 Journal of Neuroscience. Recent ...
The American Journal of Managed Care

Key Considerations for Optimizing B-VEC in Dystrophic Epidermolysis Bullosa

Beremagene geperpavec-svdt (B-VEC) entered the market in 2023 as the first approved corrective treatment for dystrophic epidermolysis bullosa (DEB), a rare genetic disease affecting the skin and nails ...
Healio

Topical gene therapy improves ocular complications of dystrophic epidermolysis bullosa

Please provide your email address to receive an email when new articles are posted on . More than a quarter of patients with DEB experience ocular complications. A single patient showed complete ...
The American Journal of Managed Care

FDA Approves Prademagene Zamikeracel for Recessive Dystrophic Epidermolysis Bullosa

Prademagene zamikeracel (Zevaskyn) is the first and only cell-based gene therapy for wound treatment in patients with recessive dystrophic epidermolysis bullosa. The approval is based on the pivotal ...
STAT

FDA approves first treatment for skin condition that causes persistent wounds, a redosable gene therapy

The Food and Drug Administration on Friday approved the first treatment for a devastating condition that causes the skin to be so fragile that even a touch can cause it to splinter, bringing another ...
Medscape

Dystrophic Epidermolysis Bullosa: FDA Approves Labeling Changes for Topical Gene Therapy

The FDA has approved an updated label for beremagene geperpavec-svdt (B-VEC), a topical gene therapy for dystrophic epidermolysis bullosa (DEB), which expands the indication from ages 6 months and ...
The New England Journal of Medicine

Trial of Beremagene Geperpavec (B-VEC) for Dystrophic Epidermolysis Bullosa

Dystrophic epidermolysis bullosa is a rare genetic blistering skin disease caused by mutations in COL7A1, which encodes type VII collagen (C7). Beremagene geperpavec (B-VEC) is a topical ...
Healio

Dystrophic toenails in a 4-year-old boy

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. A 4-year-old boy presents with concern for toenail ...